BioAge Labs Q3 2026 Results: Net Loss of $33.5M, Loss Widens
BioAge Labs reported a net loss of $81.9 million for the nine months ended September 30, 2026, compared to $54.7 million for the same period in 2025, driven primarily by a significant increase in research and development expenses. The company strengthened its balance sheet through an underwritten stock offering and at-the-market sales, ending the period with $352.3 million in cash, cash equivalents, and marketable securities.
- Key figure
- Net loss $33.5M